Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
Status:
Recruiting
Trial end date:
2023-10-25
Target enrollment:
Participant gender:
Summary
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life
and duration of protection is critical to vaccine effectiveness in protection from oncogenic
hrHPV infection. HIV-infected individuals have an increased risk for HPV infection, and
persistent infection.
Most vaccine efficacy data among HIV-infected adolescents is represented by immunogenicity
data, and there is little published literature on vaccine effectiveness as assessed by
persistent incident genital HPV infection.
Investigators shall re-enroll a cohort of previously vaccinated HIV-infected girls and boys
for assessment of genital HPV infection 9-years post initial 3 doses of vaccination with
quadrivalent HPV vaccine at ages 9 to 14 years.